Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Other Non-Current Assets (2019 - 2025)

Historic Other Non-Current Assets for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $10.3 million.

  • Allogene Therapeutics' Other Non-Current Assets changed 0.0% to $10.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.3 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $10.3 million for FY2024, which is 0.0% changed from last year.
  • Allogene Therapeutics' Other Non-Current Assets amounted to $10.3 million in Q3 2025, which was down 0.0% from $10.3 million recorded in Q2 2025.
  • Allogene Therapeutics' 5-year Other Non-Current Assets high stood at $10.3 million for Q4 2021, and its period low was $9.4 million during Q1 2021.
  • Over the past 5 years, Allogene Therapeutics' median Other Non-Current Assets value was $10.3 million (recorded in 2021), while the average stood at $10.2 million.
  • Within the past 5 years, the most significant YoY rise in Allogene Therapeutics' Other Non-Current Assets was 11979.53% (2021), while the steepest drop was 0.0% (2021).
  • Quarter analysis of 5 years shows Allogene Therapeutics' Other Non-Current Assets stood at $10.3 million in 2021, then changed by 0.0% to $10.3 million in 2022, then changed by 0.0% to $10.3 million in 2023, then changed by 0.0% to $10.3 million in 2024, then changed by 0.0% to $10.3 million in 2025.
  • Its Other Non-Current Assets stands at $10.3 million for Q3 2025, versus $10.3 million for Q2 2025 and $10.3 million for Q1 2025.